BCTX
BriaCell Therapeutics Corp.
Biotechnology
Market Cap$5M
5Y Perf.-15.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BCTX vs AZN
Revenue, margins, valuation, and 5-year total return — side by side.
AZN
AstraZeneca PLC
Drug Manufacturers - General
Market Cap$282.96B
5Y Perf.+70.2%
BCTX vs AZN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BCTX | AZN |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - General |
| Market Cap | $5M | $282.96B |
| Revenue (TTM) | $0.00 | $60.44B |
| Net Income (TTM) | $-38M | $10.39B |
| Gross Margin | — | 81.7% |
| Operating Margin | — | 23.7% |
| Forward P/E | — | 17.7x |
| Total Debt | $0.00 | $29.70B |
| Cash & Equiv. | $14M | $5.71B |
BCTX vs AZN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BCTX
AZN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BriaCell Therapeuti… (BCTX) | 100 | 84.9 | -15.1% |
| AstraZeneca PLC (AZN) | 100 | 170.2 | +70.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BCTX vs AZN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AZN leads in 6 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
BCTX
BriaCell Therapeutics Corp.
The Specific-Use Pick
In this particular matchup, BCTX is outpaced on most metrics by others in the set.
Best for: healthcare exposure
AZN
AstraZeneca PLC
The Income Pick
AZN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 4 yrs, beta 0.67, yield 1.8%
- Rev growth 8.6%, EPS growth 190.7%, 3Y rev CAGR 9.8%
- 268.6% 10Y total return vs BCTX's -99.2%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AZN | 8.6% revenue growth vs BCTX's -136.6% |
| Quality / Margins | AZN | 17.2% margin vs BCTX's 0.4% |
| Stability / Safety | AZN | Beta 0.67 vs BCTX's 1.56 |
| Dividends | AZN | 1.8% yield; 4-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | AZN | +33.9% vs BCTX's -87.5% |
| Efficiency (ROA) | AZN | 9.1% ROA vs BCTX's -153.6%, ROIC 14.9% vs -12.6% |
BCTX vs AZN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
BCTX vs AZN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAZNLAGGINGBCTX
BCTXBriaCell Therapeutics…
2leads
AZNAstraZeneca PLC
3leads
6 Total Categories
CATEGORYLEADERvs BCTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BCTX1/1
Valuation MetricsMultiples, price ratios, and targets
BCTX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AZN6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
AZN5/5
Risk & VolatilityBeta, volatility, and downside exposure
AZN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BCTX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AZN and BCTX operate at a comparable scale, with $60.4B and $0 in trailing revenue.
| Metric | BCTXBriaCell Therapeu… | AZNAstraZeneca PLC |
|---|---|---|
| RevenueTrailing 12 months | $0 | $60.4B |
| EBITDAEarnings before interest/tax | -$43M | $20.1B |
| Net IncomeAfter-tax profit | -$38M | $10.4B |
| Free Cash FlowCash after capex | -$37M | $9.1B |
| Gross MarginGross profit ÷ Revenue | — | +81.7% |
| Operating MarginEBIT ÷ Revenue | — | +23.7% |
| Net MarginNet income ÷ Revenue | — | +17.2% |
| FCF MarginFCF ÷ Revenue | — | +15.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +12.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +92.3% | +5.3% |
BCTX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
BCTX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | BCTXBriaCell Therapeu… | AZNAstraZeneca PLC |
|---|---|---|
| Market CapShares × price | $5M | $283.0B |
| Enterprise ValueMkt cap + debt − cash | -$9M | $306.9B |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | 27.91x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.74x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.28x |
| EV / EBITDAEnterprise value multiple | — | 15.76x |
| Price / SalesMarket cap ÷ Revenue | — | 4.82x |
| Price / BookPrice ÷ Book value/share | 0.32x | 5.85x |
| Price / FCFMarket cap ÷ FCF | — | 24.05x |
BCTX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
AZN leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
AZN delivers a 22.2% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-194 for BCTX. On the Piotroski fundamental quality scale (0–9), AZN scores 8/9 vs BCTX's 1/9, reflecting strong financial health.
| Metric | BCTXBriaCell Therapeu… | AZNAstraZeneca PLC |
|---|---|---|
| ROE (TTM)Return on equity | -193.8% | +22.2% |
| ROA (TTM)Return on assets | -153.6% | +9.1% |
| ROICReturn on invested capital | -12.6% | +14.9% |
| ROCEReturn on capital employed | -3.4% | +17.2% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 8 |
| Debt / EquityFinancial leverage | — | 0.61x |
| Net DebtTotal debt minus cash | -$14M | $24.0B |
| Cash & Equiv.Liquid assets | $14M | $5.7B |
| Total DebtShort + long-term debt | $0 | $29.7B |
| Interest CoverageEBIT ÷ Interest expense | -796.67x | 8.43x |
AZN leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
AZN leads this category, winning 5 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AZN five years ago would be worth $18,221 today (with dividends reinvested), compared to $83 for BCTX. Over the past 12 months, AZN leads with a +33.9% total return vs BCTX's -87.5%. The 3-year compound annual growth rate (CAGR) favors AZN at 9.3% vs BCTX's -84.4% — a key indicator of consistent wealth creation.
| Metric | BCTXBriaCell Therapeu… | AZNAstraZeneca PLC |
|---|---|---|
| YTD ReturnYear-to-date | -42.8% | +1.1% |
| 1-Year ReturnPast 12 months | -87.5% | +33.9% |
| 3-Year ReturnCumulative with dividends | -99.6% | +30.4% |
| 5-Year ReturnCumulative with dividends | -99.2% | +82.2% |
| 10-Year ReturnCumulative with dividends | — | +268.6% |
| CAGR (3Y)Annualised 3-year return | -84.4% | +9.3% |
AZN leads this category, winning 5 of 5 comparable metrics.
Risk & Volatility
AZN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AZN is the less volatile stock with a 0.67 beta — it tends to amplify market swings less than BCTX's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AZN currently trades 85.8% from its 52-week high vs BCTX's 11.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BCTXBriaCell Therapeu… | AZNAstraZeneca PLC |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 0.67x |
| 52-Week HighHighest price in past year | $37.20 | $212.71 |
| 52-Week LowLowest price in past year | $3.60 | $91.44 |
| % of 52W HighCurrent price vs 52-week peak | +11.0% | +85.8% |
| RSI (14)Momentum oscillator 0–100 | 50.0 | 39.1 |
| Avg Volume (50D)Average daily shares traded | 185K | 1.9M |
AZN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
AZN is the only dividend payer here at 1.78% yield — a key consideration for income-focused portfolios.
| Metric | BCTXBriaCell Therapeu… | AZNAstraZeneca PLC |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $211.00 |
| # AnalystsCovering analysts | — | 41 |
| Dividend YieldAnnual dividend ÷ price | — | +1.8% |
| Dividend StreakConsecutive years of raises | — | 4 |
| Dividend / ShareAnnual DPS | — | $3.25 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.3% |
Insufficient data to determine a leader in this category.
Key Takeaway
AZN leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). BCTX leads in 2 (Income & Cash Flow, Valuation Metrics).
Best OverallAstraZeneca PLC (AZN)Leads 3 of 6 categories
Loading custom metrics...
BCTX vs AZN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BCTX or AZN a better buy right now?
AstraZeneca PLC (AZN) offers the better valuation at 27.
9x trailing P/E (17. 7x forward), making it the more compelling value choice. Analysts rate AstraZeneca PLC (AZN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BCTX or AZN?
Over the past 5 years, AstraZeneca PLC (AZN) delivered a total return of +82.
2%, compared to -99. 2% for BriaCell Therapeutics Corp. (BCTX). Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BCTX or AZN?
By beta (market sensitivity over 5 years), AstraZeneca PLC (AZN) is the lower-risk stock at 0.
67β versus BriaCell Therapeutics Corp. 's 1. 56β — meaning BCTX is approximately 134% more volatile than AZN relative to the S&P 500.
04Which is growing faster — BCTX or AZN?
On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190.
7% year-over-year, compared to -44. 5% for BriaCell Therapeutics Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BCTX or AZN?
AstraZeneca PLC (AZN) is the more profitable company, earning 17.
5% net margin versus 0. 0% for BriaCell Therapeutics Corp. — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZN leads at 23. 4% versus 0. 0% for BCTX. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BCTX or AZN?
In this comparison, AZN (1.
8% yield) pays a dividend. BCTX does not pay a meaningful dividend and should not be held primarily for income.
07Is BCTX or AZN better for a retirement portfolio?
For long-horizon retirement investors, AstraZeneca PLC (AZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
67), 1. 8% yield, +268. 6% 10Y return). BriaCell Therapeutics Corp. (BCTX) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BCTX and AZN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
AZN pays a dividend while BCTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.